Atopic Dermatitis | AbbVie | ABT-494
Pharmaceutical Company/Sponsor:
AbbVie
Code:
ABT-494
Title:
A phase 2b multicenter, randomized, placebo-controlled, double-blind dose-ranging study to evaluate ABT-494 in adult subjects with moderate to severe atopic dermatitis
Type:
Phase:
Condition/Disease:
Atopic Dermatitis
Intervention(s)/Treatment(s):
Status:
Completed
Link for Additional Information:
